Specially, resmetirom (MGL-3196), an orally active, selective TH receptor β1 (THRβ1) agonist to treat obesity and hypercholesterolemia, reduced hepatic fat content at week 12, with a greater proportion of treated patients showing pathological improvement in liver biopsy samples (26). The gene discussed is THRB; the disease is obesity due to melanocortin 4 receptor deficiency.